Gene Therapy Trial Wrenches Families as One Child’s Death Saves Another
By Antonio Regalado,
MIT Technology Review
| 07. 20. 2016
An important test of gene therapy in Italy is bringing joy and heartbreak to families afflicted with a rare brain disease by offering affected siblings unequal shots at life.
Amy Price, an American from Omaha, Nebraska, says that in 2011 she did something no mother should have to, leaving one sick toddler behind at a rented flat in Milan with caretakers while accompanying her younger infant for a life-saving treatment at an Italian hospital.
...
The therapy involves adding a correct copy of a single gene to a child’s bone marrow. But it only works well if it’s given before symptoms develop: by the time most children, including Liviana, are diagnosed it’s too late. The exception is when a family is alerted by one sick child that others are at risk. Then genetic and biochemical tests can discover if there’s a disease threat in younger children.
Continue reading on MIT Technology Review
Image via Flickr/South Florida Sun
Related Articles
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Gabriele Pichlhofer and Tino Plümecke, Guest Contributors
| 03.25.2026
A German translation of this interview will be published in May 2026 in the German GID MAGAZIN, which focuses on the market for reproductive technologies. For more information, visit: Gen-ethisches Netzwerk
Egg donation is currently prohibited in Germany and Switzerland, but both countries have been debating its legalization for years. In Switzerland, a legal framework is currently being developed, with a first draft expected by the end of the year. Yet the debate rarely draws on scientific evidence. Instead...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Ritsuko Kawai, Wired | 03.14.2026
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will...